Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 20/20 | 1.00 |
| ▸ | POT1 | Q9NUX5 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13989197 | 0.95 | TERT (1.00) | TERTPOT1 | |
| SCHEMBL13989194 | 0.88 | TERT (0.85) | TERTPOT1 | |
| SCHEMBL13989192 | 0.84 | TERT (1.00) | TERTPOT1 | |
| SCHEMBL31237593 | 0.84 | TERT (0.78) | TERTPOT1 | |
| SCHEMBL13989208 | 0.84 | TERT (0.77) | TERTPOT1 | |
| SCHEMBL13989209 | 0.84 | TERT (0.78) | TERTPOT1 | |
| SCHEMBL13989193 | 0.83 | TERT (0.80) | TERTPOT1 | |
| SCHEMBL13989200 | 0.83 | TERT (1.00) | TERTPOT1 | |
| SCHEMBL13989195 | 0.83 | TERT (1.00) | TERTPOT1 | |
| SCHEMBL13989205 | 0.83 | TERT (1.00) | TERTPOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319001-A1 | Cancer Treatment Using Specific 3,6,9-Substituted Acridines | CANCER RESEARCH TECHNOLOGY LTD (GB) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319001-A1 | Cancer Treatment Using Specific 3,6,9-Substituted Acridines | FOLR1, TP53, FOLR2 | TERT 181/4885POT1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.